This laboratory has reported previously that ⌬ 9 -tetrahydrocannabinol (⌬ 9 -THC) and cannabinol (CBN) robustly elevate intracellular calcium ([Ca 2ϩ ] i ) in resting human and murine T cells, whereas CP55,940 [5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol], a high-affinity ligand for CB1 and CB2, does not. In light of our previous studies, the objective of the present investigation was to examine the ability of various cannabinoid compounds to elevate [Ca 2ϩ ] i in the CB2 receptor-expressing human peripheral blood acute lymphoid leukemia T cell line and the dependence of structural similarity to ⌬ 9 -THC therein. The present studies demonstrate that CBN and HU-210 Ϫ/Ϫ /CB2 Ϫ/Ϫ mouse splenocytes. Taken together, the present results demonstrate that classic tricyclic cannabinoids with structural similarity to ⌬ 9 -THC elicit a robust influx of calcium in T cells putatively through receptor-operated cation channels in a manner sensitive to the cannabinoid receptor antagonists, but independent of the CB1 and CB2 receptors.
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Ϫ/Ϫ /CB2 Ϫ/Ϫ mice showed that the [Ca 2ϩ ] i elevation elicited by all three tricyclic cannabinoids was independent of CB1 and CB2. Moreover, both the CB1 and CB2 receptor antagonists attenuated that rise in [Ca 2ϩ ] i elicited by the tricyclic cannabinoids in the wild-type and CB1
Ϫ/Ϫ /CB2 Ϫ/Ϫ mouse splenocytes. Taken together, the present results demonstrate that classic tricyclic cannabinoids with structural similarity to ⌬ 9 -THC elicit a robust influx of calcium in T cells putatively through receptor-operated cation channels in a manner sensitive to the cannabinoid receptor antagonists, but independent of the CB1 and CB2 receptors.
The immunosuppressive properties of plant-derived cannabinoids have been widely investigated (Schatz et al., 1993; Condie et al., 1996; Klein et al., 2000) . ⌬ 9 -Tetrahydrocannabinol (⌬ 9 -THC), the most extensively investigated cannabinoid, exhibits a broad range of immunomodulatory activity. The immunomodulatory effects of ⌬ 9 -THC include direct effects on T cell function as evidenced by altered mitogeninduced cell proliferation, suppressed accessory cell function in T cell-dependent antibody responses, and altered production of several T cell-derived cytokines (Schatz et al., 1993; Condie et al., 1996; Newton et al., 1998; Klein et al., 2000) . Despite extensive investigation, the specific mechanism responsible for altered T cell function by cannabinoids remains poorly understood. However, because immune cells express both cannabinoid receptors CB1 and CB2, the mechanism by which cannabinoids elicit their immunomodulatory effects is generally believed to be mediated by one or both cannabinoid receptors (Klein et al., 2003; Howlett et al., 2004) .
Recent studies of cannabinoid-mediated effects in various systems, including the immune system, have produced an increasing body of evidence suggesting the existence of novel receptors and/or nonreceptor cellular targets through which cannabinoids influence biological responses. Most notably, biochemical and pharmacological studies in the murine brain and in endothelial cells have provided the strongest indications yet for the existence of uncharacterized cannabinoid receptors (Breivogel et al., 2001; Wiley and Martin, 2002; Offertaler et al., 2003; Mo et al., 2004) . In addition, previous investigations from this and other laboratories have demonstrated CB1 and CB2 receptor-independent effects of cannabinoids in immune cells (Faubert Kaplan et al., 2003; Sancho et al., 2003; Kraft et al., 2004) . The modulation of interleukin-2 production by cannabinoids in activated T cells, in particular, has been shown to be insensitive to treatment with the cannabinoid receptor antagonists (Jan et al., 2002; Faubert Kaplan et al., 2003; Rockwell and Kaminski, 2004) . By contrast, in unstimulated T cells, ⌬ 9 -THC and CBN induced a robust elevation of intracellular calcium ([Ca 2ϩ ] i ), which was sensitive to both cannabinoid receptor antagonists, SR141716A (SR1) and SR144528 (SR2) (Faubert Kaplan et al., 2003; Rao et al., 2004) . However, CP55,940, a high-affinity CB1/CB2-nonselective agonist, could not elevate [Ca 2ϩ ] i , which raised the possibility that antagonism of the cannabinoid-mediated [Ca 2ϩ ] i rise by SR1 and SR2 may not imply CB1 or CB2 dependence (Rao et al., 2004) .
In T cells, the elevation of [Ca 2ϩ ] i is an important signaling event. [Ca 2ϩ ] i is involved in positive and negative regulation of the expression of several genes. The elevation of [Ca 2ϩ ] i occurs in two distinct phases upon the activation of the T cell antigen receptor. The first rapid phase is characterized by a modest release of stored intracellular calcium followed by a slower, yet larger, second phase produced from extracellular calcium ([Ca 2ϩ ] e ) influx (Lewis, 2001; Winslow et al., 2003) . The influx of [Ca 2ϩ ] e , which accounts for the bulk of the [Ca 2ϩ ] i elevation, is attributed to a highly specialized variety of store-operated calcium channels known as the calciumrelease activated calcium channels. Once the [Ca 2ϩ ] i levels are elevated, transcription factors such as NFAT are activated and can proceed to modulate gene expression (Feske et al., 2001; Lewis, 2001) . Conversely, if [Ca 2ϩ ] i is elevated in T cells before cellular activation, T cells can enter a state of nonresponsiveness known as T cell anergy (Harding et al., 1992; Nakayama et al., 1992; Schwartz, 1992; Nghiem et al., 1994; Faubert Kaplan et al., 2003) .
The critical role for [Ca 2ϩ ] i in T cells coupled with our prior observation that the cannabinoid-mediated [Ca 2ϩ ] i elevation was putatively CB1-and CB2-dependent prompted the present characterization of [Ca 2ϩ ] i elevation by various cannabinoids. The objective of the present investigation was to examine whether a structure-activity relationship exists for cannabinoid-induced [Ca 2ϩ ] i elevation and to elucidate the role of CB1 and CB2 receptors in this process. The importance of the investigation is especially critical in determining whether the cannabinoid-induced effects are mediated through a specific or nonspecific mechanism of action. Therefore, in the present studies we examined the mechanism of [Ca 2ϩ ] i elevation by tricyclic cannabinoids in the CB2 receptor-expressing HPB-ALL human T cell line and splenocytes derived from wild-type and CB1
Ϫ/Ϫ /CB2 Ϫ/Ϫ mice. All experiments were performed in the absence of T cell activation to eliminate the confounding variable of T cell activation-dependent elevation in [Ca 2ϩ Cell Culture. The HPB-ALL human T cell line was generously provided by Dr. Jeffrey A. Ledbetter (Pacific Northwest Research Institute). HPB-ALL cells were cultured in RPMI 1640 medium (Gibco BRL, Grand Island, NY) supplemented with 100 units of penicillin/ml, 100 units of streptomycin/ml, 10% bovine calf serum (Hyclone, Logan, UT), 100 mM nonessential amino acids (Gibco BRL, Grand Island, NY), and 1 mM sodium pyruvate (Gibco BRL).
Animals. Pathogen-free female C57BL/6J mice, 6 weeks, were purchased from Charles River Breeding Laboratories (Portage, MI). On arrival, mice were randomized, transferred to plastic cages containing sawdust bedding (five animals per cage), and quarantined for 1 week. Pathogen-free C57BL/6J CB1 Ϫ/Ϫ /CB2 Ϫ/Ϫ mice were generously provided by Dr. Andreas Zimmer (University of Bonn, Bonn, Germany). C57BL/6J CB1 Ϫ/Ϫ /CB2 Ϫ/Ϫ mice were bred at the University Laboratory Animal Resources (Michigan State University). All mice were given food (Purina Certified Laboratory Chow; Purina, St. Louis, MO) and water ad libitum. Mice were not used for experimentation until their body weight was 17 to 20 g. Animal-holding rooms were maintained at 21 to 24°C and 40 to 60% relative humidity with a 12-h light/12-h dark cycle. All studies were performed in compliance with the Michigan State University Institutional Animal Care and Use Committee.
Splenocyte Preparation. Splenocytes from C57BL/6J wild-type or CB1
Ϫ/Ϫ /CB2 Ϫ/Ϫ mice were made into single-cell suspensions and depleted of red blood cells using ACK lysing buffer (10 M EDTANa 2 , 10 mM KHCO 3 , and 150 mM NH 4 Cl) for 5 min at room temperature. The cell suspension was washed repeatedly with RPMI 1640 medium. The collected leukocytes were then resuspended in Ca 2ϩ -KREB buffer (129 mM NaCl, 5 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 1 mM CaCl 2 , 5 mM NaHCO 3 , 10 mM HEPES, 2.8 mM glucose, and 0.2% bovine serum albumin) for calcium determinations.
Calcium Determination. Cells were washed twice in Ca 2ϩ -KREB buffer. For studies conducted in the absence of extracellular calcium, the Ca 2ϩ -KREB buffer was prepared as above without CaCl 2 and supplemented with 1 mM MgCl 2 and 20 M EGTA. [Ca 2ϩ ] i was determined by measuring the fluorescence of fura-2 dye, which is dually excited at 340 and 380 nm. In brief, cells were incubated with cell-permeant fura-2-AM (1 M; Molecular Research Products, Eugene, OR) for 30 min at 37°C in the dark. Cells were harvested, washed twice with Ca 2ϩ -KREB buffer to remove extracellular fura-2 dye, and adjusted to 5 ϫ 10 5 cells/ml (for HPB-ALL cells) or 5 ϫ 10 6 cells/ml (for splenocytes) in Ca 2ϩ -KREB buffer. Cells were placed in a 3-ml quartz cuvette with constant stirring. Calcium determinations were performed at room temperature with a Beckman Spex 1681 0.22m spectrometer with dual excitation at 340 and 380 nm and emission at 510 nm (all slit widths were 1 mm). The dissociation constant for the fura-2-calcium complex was 1.45 ϫ 10 Ϫ7 M. All compounds used in intracellular calcium determination were screened for autofluorescence using fura-2 sodium salt containing Ca 2ϩ -KREB buffer. None of the compounds, with the exception of WIN 55,212-2, interfered with fura-2 measurements. (Rao et al., 2004) , the primary focus of the present investigation was to determine whether a structure-activity relationship exists for cannabinoid-induced [Ca 2ϩ ] i elevation. Here, both CBN and HU-210 (Fig. 1A) elicited a robust and concentration-responsive elevation of [Ca 2ϩ ] i in the HPB-ALL cells, with a significant increase in [Ca 2ϩ ] i at concentrations greater than 10 M. However, in comparison with ⌬ 9 -THC, the magnitude of [Ca 2ϩ ] i elevation by both CBN ( Fig. 2A ) and HU-210 (Fig. 2B ) at all concentrations (1-20 M) was modest. At a concentration of 20 M, the rise in [Ca 2ϩ ] i elicited by CBN (185.5 Ϯ 50.4 nM; n ϭ 4) and HU-210 (200.3 Ϯ 13.9 nM; n ϭ 3) was similar and significantly smaller than the [Ca 2ϩ ] i elevation induced by 12.5 M ⌬ 9 -THC (870.6 Ϯ 38.7 nM; n ϭ 4). Interestingly, the [Ca 2ϩ ] i rise elicited by all three classic tricyclic cannabinoid compounds followed a significant time delay after injection of the cannabinoid into the cuvette. In addition, the time delay to onset of ] i elevation was independent of intracellular calcium stores. Therefore, the putative involvement of calcium store-independent receptor-operated cation (ROC) channels was investigated. It has been reported previously that SK&F96365 (SKF) is a potent inhibitor of ROC channels in the 10 to 50 M concentration range (Merritt et al., 1990; Wu et al., 2005) . Here, calcium measurements were performed in cells treated with SKF (20 -50 M) for 300 s before treatment with cannabinoids. In these studies, SKF inhibited the rise in [Ca 2ϩ ] i elicited by both CBN (Fig. 4A ) and HU-210 (Fig. 4B ). Interestingly, SKF was differentially efficacious in inhibiting the CBN-and HU-210-induced rise in [Ca 2ϩ ] i . At a concentration of 50 M, SKF potently inhibited the CBN-induced elevation in [Ca 2ϩ ] i by 96.7 Ϯ 1.2% (n ϭ 3). At the same concentration, SKF was less efficacious in inhibiting the HU-210-mediated rise in [Ca 2ϩ ] i as evidenced by a 47.5 Ϯ 13.6% attenuation (n ϭ 3). Another rather unusual effect of SKF pretreatment was that it reduced the time delay to onset of the HU-210-induced [Ca 2ϩ ] i elevation but not the CBN-induced [Ca 2ϩ ] i elevation. Compared with vehicle control, the time delay to onset of [Ca 2ϩ ] i elevation for HU-210 in the presence of SKF (50 M) was reduced by 165.3 Ϯ 1.2 s (n ϭ 3). Cannabinoids are widely reported to exert their biological activity through the two known cannabinoid receptors, CB1 and CB2. However, the K d values for cannabinoid agonist binding to both CB1 and CB2 are in the low-to mid-nanomolar range (Pertwee, 1999b) . In the present studies, an effect on [Ca 2ϩ ] i by tricyclic cannabinoids was not observed until micromolar concentrations were reached. To address the discrepancy of whether ] i elevation occurs through the activation of the CB2 receptor, calcium measurements were performed in the presence of the CB2 receptor antagonist SR2 (1-5 M). Previous studies have shown that the ⌬ 9 -THC-induced [Ca 2ϩ ] i elevation in HPB-ALL cells was sensitive not only to SR2 but also to the CB1 receptor antagonist, SR1 (Rao et al., 2004) . Therefore, parallel calcium measurements were also performed with SR1 (1-5 M). HPB-ALL cells were pretreated with either SR2 or SR1 for 300 s before the addition of cannabinoids. In the presence of either SR2 or SR1, a concentration-responsive attenuation of both the CBN-as well as the HU-210-mediated rise in [Ca 2ϩ ] i was observed (Table 1) . Interestingly, whereas the elevation in [Ca 2ϩ ] i elicited by CBN was equally sensitive to both antagonists, the HU-210-induced [Ca 2ϩ ] i rise was more sensitive to SR1 than to SR2. Compared with the vehicle control, both SR2 (5 M) and SR1 (5 M) strongly attenuated the magnitude of [Ca 2ϩ ] i rise elicited by CBN by 70.9 Ϯ 3.4% (n ϭ 3) and 71.9 Ϯ 2.3% (n ϭ 3), respectively. In contrast, the HU-210-induced [Ca 2ϩ ] i rise was strongly attenuated by SR1 (5 M; 97.6 Ϯ 1.1% inhibition; n ϭ 3) but only modestly by SR2 (5 M; 29.1 Ϯ 6.9% inhibition; n ϭ 4).
Effect of CBD on [Ca
2؉ ] i in HPB-ALL Cells. In addition to the tricyclic classic cannabinoids, the structure-activity relationship on [Ca 2ϩ ] i elevation was also assessed in the HPB-ALL cells using a nonclassic bicyclic cannabinoid, CBD (Fig. 1B) . Apart from its structural dissimilarity to the tricyclic cannabinoids, CBD is considered not to act as an agonist at either the CB1 or CB2 receptors (Pertwee, 1999b) . Treatment of HPB-ALL cells with CBD (1-20 M), nonetheless, produced a small increase in [Ca 2ϩ ] i (Fig. 5A) . However, in contrast with the [Ca 2ϩ ] i elevation profiles of HU-210, CBN, and ⌬ 9 -THC, the [Ca 2ϩ ] i rise elicited by CBD was very modest, rapid, and not concentration-responsive (Fig. 5A ). In addition, the CBD-induced [Ca 2ϩ ] i rise occurred in two distinct phases-a rapid first phase and a slower second phase. Biphasic [Ca 2ϩ ] i elevation has previously been established in lymphocytes to be a characteristic of store-operated calcium entry (Parekh, 2003) . To investigate the possibility that CBD was eliciting a release of stored intracellular calcium, cells were treated with CBD (10 M) either in the presence or absence of [Ca 2ϩ ] e . The results showed that, although the first phase of the CBD-induced [Ca 2ϩ ] i rise was maintained in the absence of [Ca 2ϩ ] e , the second delayed phase was completely abolished (Fig. 5B) . The insensitivity of the first phase to [Ca 2ϩ ] e indicates that CBD elicits a store release followed by [Ca 2ϩ ] e influx. Finally, the effect of SR2 on the CBD-induced [Ca 2ϩ ] i rise was assessed. Cells were pretreated with SR2 (5 M) for 300 s before CBD (10 M) addition. Unlike the [Ca 2ϩ ] i elevation elicited by CBN and HU-210, the CBD-mediated elevation of [Ca 2ϩ ] i was insensitive to SR2 (Fig. 5C) . ] i elevation could not be assessed due to its interference with fura-2 calcium measurements. On the other hand, JWH-133, a high-affinity CB2-selective agonist, did not interfere with calcium measurements but interestingly did not induce an elevation of [Ca 2ϩ ] i over a range of concentrations (0.1-20 M) in the HPB-ALL cells (data not shown). Finally, the endocannabinoids (Fig. 1C) 1% DMSO for HU-210) was injected into the cuvette and the increase in ͓Ca 2ϩ ͔ i was measured for 1600 s. ͓Ca 2ϩ ͔ i changes are presented as changes in the mean change in base to peak ratio Ϯ S.E.M. of bound to free calcium (340/380 nm). The calcium data represent a mean of at least three independent experiments. 
Discussion
Previous work from this laboratory has established in various T cell preparations that plant-derived cannabinoids, ⌬ 9 -THC and CBN, elevated [Ca 2ϩ ] i , whereas the high-affinity synthetic cannabinoid, CP55,940, did not (Faubert Kaplan et al., 2003; Rao et al., 2004) . Furthermore, the elevation of [Ca 2ϩ ] i by both ⌬ 9 -THC and CBN was antagonized by SR1 and SR2 and, therefore, deemed cannabinoid receptor-dependent (Faubert Kaplan et al., 2003; Rao et al., 2004) . Using the HPB-ALL cells and SPLCs from WT and CB1 Ϫ/Ϫ /CB2
Ϫ/Ϫ mice, in the present studies, we reexamined the premise that CB1 and CB2 receptors are involved in the cannabinoidmediated elevation in [Ca 2ϩ ] i in T cells. In addition, these studies also characterized the structure-activity relationship of various cannabinoids on the elevation of [Ca 2ϩ ] i . The current characterization provides several lines of evi- ] i elevation was attenuated by both antagonists with similar sensitivities, the HU-210-mediated [Ca 2ϩ ] i elevation was more sensitive to SR1 than to SR2, even in the HPB-ALL cells, which do not express CB1 (Schatz et al., 1997; Rao et al., 2004) . Second, the time delay to onset of the [Ca 2ϩ ] i elevation varied for the different cannabinoids. The time delay to onset of the [Ca 2ϩ ] i rise was dependent on the cell model, the compound, and the concentration applied to the cells. At present, the significance of the varying time delays to onset of the [Ca 2ϩ ] i rise is unclear but may represent a delay in signaling cascades. A final difference between the [Ca 2ϩ ] i responses of the three cannabinoids is their sensitivity to the Ϫ/Ϫ /CB2 Ϫ/Ϫ SPLCs, it is clear that the tricyclic cannabinoid-mediated elevation in [Ca 2ϩ ] i is independent of CB1 and CB2 but can be antagonized by both SR1 and SR2.
The present studies provide several broad insights to allude to the involvement of a yet unknown cannabinoid receptor in T cells. First, the concentrations of cannabinoids and cannabinoid antagonists required to elicit and antagonize the [Ca 2ϩ ] i elevation, respectively, exceed the binding affinities for either CB1 or CB2 by several orders of magnitude. For example, HU-210 has much higher affinity for the CB2 receptor than CBN or ⌬ 9 -THC (Pertwee, 1999a; Berdyshev, 2000; Klein et al., 2003) Based on the available data and the sensitivity to SR1 and SR2, previous publications from this laboratory had indicated the logical conclusion that the cannabinoid-mediated [Ca 2ϩ ] i elevation was dependent on the CB1 and CB2 receptors (Faubert Kaplan et al., 2003; Rao et al., 2004) . By contrast, the present studies using WT and CB1 Ϫ/Ϫ /CB2
SPLCs clearly indicate that previous conclusions on the dependence of CB1 and CB2 for [Ca 2ϩ ] i elevation were incorrect on the basis of the unanticipated off-target effects elicited by SR1 and SR2. The current studies argue that tricyclic cannabinoids induce a robust influx of [Ca 2ϩ ] e in a SR1-and SR2-sensitive but CB1 and CB2 receptor-independent manner. Although the precise mechanism through which cannabinoids elevate [Ca 2ϩ ] i remains largely elusive, our studies effectively show that measurement of [Ca 2ϩ ] i is one functional response that may be used to characterize the putative non-CB1, non-CB2 cannabinoid receptor(s) in T cells. Another unique insight provided by the present studies is that different cannabinoids may act via diverging mechanisms of action to elevate [Ca 2ϩ ] i in T cells. Overall, these structure- 
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